Hepatocyte-like cells can be derived from pluripotent stem cells such as embryonic stem (ES) cells, but ES cell-derived hepatic cells with extensive capacity to repopulate liver have not been identified. We aimed to identify and purify ES cell-derived hepatoblast-like progenitor cells and to explore their capacity for liver repopulation in mice after in vitro expansion. METHODS: Unmanipulated mouse ES cells were cultured under defined conditions and allowed to undergo stepwise hepatic differentiation. The derived hepatic cells were examined by morphologic, fluorescenceactivated cell sorting, gene expression, and clonal expansion analyses. The capacities of ES cell-derived hepatic progenitor cells to repopulate liver were investigated in mice that were deficient in fumarylacetoacetate hydrolase (Fah) (a model of liver injury). RESULTS: Mouse ES cells were induced to differentiate into a population that contained hepatic progenitor cells; this population included cells that expressed epithelial cell adhesion molecule (EpCAM) but did not express c-Kit. Clonal hepatic progenitors that arose from single c-Kit Ϫ EpCAM ϩ cells could undergo long-term expansion and maintain hepatoblast-like characteristics. Enriched c-Kit Ϫ EpCAM ϩ cells and clonally expanded hepatic progenitor cells repopulated the livers of Fah-deficient mice without inducing tumorigenesis. CONCLUSIONS: ES cell-derived c-Kit ؊ EpCAM ؉ cells contain a population of hepatoblast-like progenitor cells that can repopulate livers of mice.
H epatic cells differentiated from embryonic stem (ES) cells or induced pluripotent stem cells would provide an unlimited cell source for cell replacement therapy, liver tissue engineering, and models of molecular pathogenesis for liver diseases. [1] [2] [3] Although hepatic differentiation from mouse and human ES cells, and recently from human induced pluripotent stem cells, has been successful, 4 -15 the derived hepatic cells were heterogeneous populations at different stages of differentiation. More importantly, hepatic cells with extensive liver repopulation capacity are yet to be identified. Without identification of pure lines of hepatic cells capable of therapeutic liver repopulation, the functionality of derived hepatic cells cannot be proven, nor will the nature of pluripotent stem cell-derived hepatic cells be fully understood. Furthermore, derived hepatic cells could be useful in clinical therapeutic cell transplantation. 1, 3, 16 Thus, the methods to purify and expand stem cell-derived functional hepatic cells may have important and practical utility.
Isolation of ES cell-derived hepatic cells was previously based on expression of selective markers controlled by promoters of hepatic genes such as ␣-fetoprotein (Afp), 4 Foxa2, 5 albumin (Alb), 6, 7 and ␣1-antitrypsin (Aat). 8 However, it will be necessary to derive genetically unmanipulated hepatic cells for therapeutic applications in the future. 1, 3, 16 Asialoglycoprotein-receptor (ASGPR) was studied as a selection marker, but it could be only be used to isolate mature hepatocyte-like cells, 11 instead of hepatic progenitor cells. Until now, there was no specific surface marker useful in identifying and enriching ES cell-derived hepatic progenitor cells. It was also unknown whether ES cell-derived hepatic progenitor cells retain differentiation potential and liver repopulation capacity after extensive proliferation in vitro.
In this study, a novel method of stepwise cell differentiation from mouse ES cells was established to derive hepatic cells, which mostly recapitulated essential stages of embryonic hepatogenesis. In our method, the derived hepatic cells characteristic of mouse embryonic hepatoblasts could be obtained as a dominant cell population in culture at day 13 of induced differentiation. This cell population could be identified and enriched in a c-Kit Ϫ epithelial cell adhesion molecule (EpCAM) ϩ cell population, which proved to be ES cell-derived hepatoblast-like progenitor cells by fluorescence activated cell sorting (FACS) analysis, morphologic characters, and gene expression patterns. Furthermore, single hepatic progenitor cells in the c-Kit Ϫ EpCAM ϩ population could be clonally selected and expanded with sustained bipotency. In cell transplantation assays, ES cell-derived hepatic progenitor cells were able to therapeutically repopulate the injured livers of fumarylacetoacetate hydrolase (Fah)-deficient mice. To our knowledge, this is the first identification and enrichment of ES-derived hepatoblast-like progenitor cells capable of therapeutic liver repopulation.
Materials and Methods

ES Cell Culture and Hepatic Differentiation
Based on and slightly modified from N2B27 medium, 17 the chemically defined medium (CDM) consists of a 1:1 mixture of neurobasal medium and Dulbecco's modified Eagle medium (DMEM)/F12 medium supplemented with 0.5X N2 and 0.5X B27 supplements, 0.1% bovine serum albumin (BSA), 2 mmol/L glutamax, and 0.1 mmol/L 2-mercaptoethanol (all from Invitrogen, Carlsbad, CA). Mouse ES cells (E14; American Type Culture Collection, Manassas, VA) were cultured on gelatincoated dishes in CDM supplemented with 10 ng/mL recombinant human bone morphogenetic protein 4 (BMP4) and 1000 U/mL leukemia inhibitory factor (LIF). To drive hepatic differentiation, ES cells digested with Cell Disassociation Buffer (Sigma-Aldrich, St. Louis, MO) were seeded (2.5 ϫ 10 3 cells/cm 2 ) on type IV Collagen (Becton Dickinson, San Jose, CA)-coated dishes in CDM supplemented with 20 ng/mL recombinant Activin A and 1 mmol/L sodium butyrate (Sigma-Aldrich) for 2 days then in CDM with 20 ng/mL Activin A for 3 days. Later, day 5 cells were replated (5 ϫ 10 4 cells/cm 2 ) on gelatin-coated dishes in hepatic progenitor specification medium (CDM supplemented with 20 ng/mL Activin A, 20 ng/mL BMP4, and 20 ng/mL fibroblast growth factor 2 [FGF2]) for 2 days, followed in hepatic progenitor expansion medium (CDM supplemented with 10 ng/mL BMP4, 10 ng/mL FGF2, 20 ng/mL hepatocyte growth factor [HGF], 20 ng/mL transforming growth factor-␣ [TGF␣], 10 ng/mL epidermal growth factor [EGF] , and 10 Ϫ7 mol/L dexamethasone ) for 6 days. The medium was changed every other day. All growth factors except LIF (ESGRO, Chemicon, Temecula, CA) were purchased from R&D (R&D Systems Inc, Minneapolis, MN).
Antibodies
Details about antibodies are available in Supplementary Table 2 .
Flow Cytometry
Cells were harvested and washed twice in washing buffer (phosphate-buffered saline [PBS] containing 0.2% BSA). One ϫ 10 5 cells were stained in 100 L washing buffer with chromophore-conjugated antibodies at 4°C for 30 minutes, followed by washing twice and analysis. Alternatively, primary antibody-bound cells were further incubated with chromophore-conjugated secondary antibodies at 4°C for 30 minutes, washed twice, and analyzed. Isotope antibodies were used as negative controls. Intracellular staining of Afp and Alb for FACS analysis was performed as described. 5 Cells were acquired using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA) and data analyzed with FlowJo software (Tree Star, Ashland, OR). Cell sorting was performed as above except that cells were acquired using a FACSAria II flow cytometer (Becton Dickinson).
In Vitro Colony Formation Assays
Sorted cell populations from mouse ES cell-derived day 13 hepatic cultures were replated (5 ϫ 10 4 cells/cm 2 ) on type I collagen (Becton Dickinson)-coated 35-mm dishes in hepatic progenitor expansion medium for 6 to 8 days, numbers of epithelial colonies containing more than 50 cells were quantified, and morphologies were examined.
Establishment of Single c-Kit
The serum-containing medium consists of DMEM/F12 medium supplemented with 10% fetal bovine serum (HyClone, Logan, UT), 1% penicillin/streptomycin, and 0.1 mmol/L 2-mercaptoethanol (Invitrogen). Day 13 c-Kit Ϫ EpCAM ϩ cells were sorted on FACSAria II to seed a single cell into individual wells in 96-well plates precultured with mitomycin C-treated mouse embryonic fibroblasts (MEF) feeder layers. Cells were maintained in serum-containing medium supplemented with 10 ng/mL HGF, 10 ng/mL EGF, 1X insulin-transferrin-selenium X (ITS), 10 Ϫ7 mol/L dexamethasone, 10 ng/mL nicotinamide, and 50 mg/mL gentamicin (all from Sigma-Aldrich). After 6 to 10 days, colonies from single cells were expanded by serial passage. Cloned cell lines were routinely cultured (5 ϫ 10 4 cells/cm 2 ) on MEF feeder layers in 6-well plates, with a split ratio of 1:3 every 2 days.
Immunohistochemistry and Immunocytochemistry
Immunohistologic detection of Fah, as well as hematoxylin and eosin (H&E) staining, has been de-scribed. 18, 19 Briefly, liver samples were fixed in 4% paraformaldehyde before paraffin embedding. Sections (2 m) were dewaxed with xylene, rehydrated, incubated with rabbit anti-mouse Fah primary antibody (1:3000) or rabbit anti-green fluorescent protein (GFP) primary antibody (1:1000), and then horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G secondary antibody, followed by detection with 3,3=-diaminobenzidine tetrahydrochloride (Dako, Glostrup, Denmark) and counterstaining with Mayer's hematoxylin solution (Sigma-Aldrich). For immunocytochemical staining, cells were fixed with PBS containing 4% paraformaldehyde at room temperature for 20 minutes and permeabilized and blocked with blocking buffer (PBS containing 0.1% Triton X-100, 1% BSA, and 10% normal donkey or goat serum) at room temperature for 45 minutes. Cells were then incubated with primary antibodies at 4°C overnight, followed by appropriate fluorescence-tagged secondary antibodies at room temperature in dark for 1 hour. Between each step, cells were washed with PBS containing 0.1% BSA. Nuclei were stained with 4=,6-diamidino-2-phenylindole (Sigma-Aldrich). Stained cells were finally examined under an Olympus IX41 (Olympus Corporation, Tokyo, Japan) fluorescence microscope. For each examination, addition of appropriate normal immunoglobulin G antibodies or secondary antibodies provided negative controls.
Animal Experiments
As in previous experiments, 18, 19 Fah Ϫ/Ϫ mice (8-to 10-weeks-old) were maintained with 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione in their drinking water. For cell transplantation, donor cells (1 ϫ 10 6 cells/recipient) in 100 L DMEM were injected intrasplenically into the mice, which were then kept on regular drinking water without 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione. 18, 19 Liver samples were harvested by partial hepatectomy at 6 weeks, and mice were killed at 10 weeks after cell transplantation. Five random serial sections derived from each left, middle, and right liver lobes were examined by immunohistochemistry analysis. The level of liver repopulation was calculated as described previously. 18, 19 Animal experiments were approved by the Institutional Animal Use Committee of the Shanghai Institutes for Biological Sciences (Chinese Academy of Sciences).
Results
Efficient Hepatic Differentiation From Mouse ES Cells
Based on previous protocols, 5, 16, 20 in combination with knowledge of signaling regulation during embryonic hepatogenesis, 21 Figure 1A) .
In stage A, mouse ES cells in adherent culture were treated with Activin A, and the treatment continued for 5 days. For the first 2 days, sodium butyrate, a histone deacethylase inhibitor, was used to promote ES cell differentiation into DE cells. 10 Immunostaining assay showed that almost all derived cells were positive for Cxcr4, a surface marker specific to both DE cells and mesoderm cells but not visceral endoderm (VE) cells, 5, 20 and the epithelial cells in clusters were positive for DE-specific genes Foxa2 and Sox17 ( Figure 1C , panel D5). (2) There was down-regulation of pluripotent genes (Oct4, Sox2, Nanog), temporary upregulation, and then decline of mesendoderm-specific genes (Mixl1, T), followed by progressive up-regulation of DE-specific genes (Cer1, Foxa2, Gsc, Gata4, Sox17) (Supplementary Figure 1A ). The dynamic gene expression patterns were consistent with those genes for differentiation of intermediate mesendoderm cells into DE cells. 23, 24 On the other hand, expression of VE-specific gene Sox7 was lower than in ES cells (Supplementary Figure 1A) , suggesting that induction of ES cells into VE cells was excluded. (3) Results of FACS analysis confirmed that almost all derived cells on day 5 were Cxcr4 ϩ cells, approximately 60% of which were positive for c-Kit (58%-62%, n ϭ 3) and/or E-cadherin (55%-61%, n ϭ 3) (Supplementary Figure 1B) . C-kit and E-cadherin were previously used as representative surface markers in combination with Cxcr4 to define ES cell-derived DE cells. 5, 20 In stage B, all the cells harvested at day 5 were replated on gelatin-coated dishes and treated with a cocktail of growth factors and chemicals for hepatic differentiation. There were dynamic changes in cellular morphology: epithelial cells with close cell contacts appeared and gradually expanded into colonies along with a few scattered cells ( Figure 1B , panel D7). The colonies then developed into large colonies with well-defined edges that were surrounded by fibroblast-like cells ( Figure 1B , panel D9). Cells in colonies continuously proliferated to become confluent in monolayer ( Figure 1B, panel D13 ). On day 13, the differentiated cells displayed epithelial morphology and had numerous vacuoles and vesicles in the cytoplasm as well as prominent nucleoli in the nuclei ( Figure  1B, panel D13) ; they expressed hepatic genes including Foxa2, cytokeratin 18 (Ck18), Afp, Alb, as well as cholangioctic genes cytokeratin 19 (Ck19), a characteristic of hepatoblasts 25 ( Figure 1C , panel D13; and Supplementary  Figure 2 ). There were dynamic changes in gene expression: DE-specific Cer1 was down-regulated, and there was sequential activation of hepatic genes Ttr and Afp from day 7 to day 13 and Aat and Alb from day 11 to day 13; carbamoyl phosphate synthetase 1 (Cps1) and tyrosine aminotransferase (Tat) were expressed only in the differentiating cells on day 13, whereas the mature hepatocytespecific gene glucose-6-phosphatase (G6p) was yet to be expressed ( Figure 1D , and Supplementary Figure 3) , which suggested that these cells were hepatic progenitor cells. Consistently, approximately 50% (45%-51%, n ϭ 3) of day 13 cells expressed Afp, and almost 60% (55%-62%, n ϭ 3) expressed Alb ( Figure 1E ). Taken together, we established an efficient and reproducible method to derive hepatic cells from mouse ES cells, and the stepwise hepatic differentiation process recapitulated essential stages of embryonic hepatogenesis.
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Isolation of c-Kit ؊ EpCAM ؉ Cells From Mouse ES Cell-Derived Hepatic Cells
To identify the hepatic progenitor cells from the whole population of ES-derived cells, we searched for and compared cell surface markers that could enrich for hepatic progenitor cells and exclude nonhepatic cells. Results of FACS analysis revealed that day 13 cells did not contain the cells positive for hematopoietic (CD34 and CD45) or endothelial (CD31) markers (Supplementary Figure 4) . In addition, day 13 cells contained significant proportions of cells positive for EpCAM and relatively low amounts of cells positive for c-Kit, Flk1, or CD140a ( Figure 2A and Supplementary Figure 4) . It was known that EpCAM was useful as a specific surface marker to isolate mouse hepatoblasts, 25 oval cells, 26 and human hepatic stem cells. 27, 28 Furthermore, hepatoblasts and hepatocytes are known to be negative for c-Kit. 29, 30 Therefore, our results and previous publications suggested that the combination of EpCAM positive and c-kit negative selection could be used to identify ES cell-derived hepatic progenitor cells. During hepatic differentiation of DE cells, we found that EpCAM ϩ cells remained a substantial proportion from day 5, whereas the percentage of c-Kit ϩ cells progressively decreased, correlating with diminishing numbers of DE cells shown by Cxcr4 down-regulation (Figure 2A ). EpCAM expression predominated in the cells of epithelial monolayer on day 13 ( Supplementary Figure 2) , correlating with the results of FACS analysis (Figure 2A) . Furthermore, when day 13 cells were sorted into 4 cell populations based on EpCAM and c-kit expression (c-Kit Ϫ EpCAM Ϫ , c-Kit ϩ EpCAM Ϫ , c-Kit ϩ EpCAM ϩ , c-Kit Ϫ EpCAM ϩ ), we found that the c-Kit Ϫ EpCAM ϩ cell population represented 40% to 45% (n ϭ 3) of total cells ( Figure 2B ) and had significantly higher expression of hepatoblast-related genes (Aat, Afp, Alb, Ck19, Ttr, Hnf1a, Hnf1b, Hnf6) in comparison with the other 3 populations ( Figure 2C ). Of note, expression of 2 early hepatic genes (Ttr and Afp) in the c-Kit Ϫ EpCAM ϩ cell population was comparable with embryonic day 13.5 fetal liver cells ( Figure 2D (Figure 3 ). In particular, colonies from c-Kit ϩ EpCAM ϩ cells were fewer in numbers, smaller in size, and mixed with some fibroblast-like cells, whereas colonies from the c-Kit Ϫ EpCAM ϩ cells were more in numbers, larger in size, and more homogenous (Figure 3) .
Collectively, these results suggest that day 13 c-Kit Ϫ EpCAM ϩ cells corresponded closely to ES cell-derived hepatic progenitor cells. On the other hand, day 13 c-Kit ϩ EpCAM ϩ cells contained residual or unsynchronized DE cells, whereas both c-Kit ϩ EpCAM Ϫ and c-Kit Ϫ EpCAM Ϫ cells were mainly mesoderm-derived cells of various lineages.
ES Cell-Derived Day 13 c-Kit ؊ EpCAM ؉ Cells Have Extensive Liver Repopulation Capacity
To determine whether the identified c-Kit Ϫ EpCAM ϩ cells could mature into functional hepatocytes in vivo, we transplanted them into livers of Fah-deficient mice, a wellestablished liver injury model. 5, 18, 19, 31 Six weeks after cell transplantation, we found repopulation nodules in 4 of 12 Fah-deficient recipients ( Figure 4A ). Repopulation nodules of significantly larger size were found in the same recipients at 10 weeks after transplantation ( Figure 4B ). Morphologically, they had normal structures of liver sinusoids and contained mature hepatocytes with Fah expression, in sharp contrast to host injured hepatocytes with disrupted cellular structures and no Fah expression ( Figure 4C and D) . To further determine whether c-Kit Ϫ EpCAM ϩ cells were the only derived cells with liver repopulation capacity, we performed cell transplantation with day 13 unsorted cells and the other 3 sorted cell populations (c-Kit Ϫ EpCAM Ϫ , c-Kit ϩ EpCAM Ϫ , c-Kit ϩ EpCAM ϩ ). Although 2 of 10 recipients transplanted with unsorted day 13 cells were found with Fahpositive hepatocytes (Figure 4E) , all of the recipients (10 recip-
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ients for each cell population) transplanted with the other 3 cell populations had no detectable engraftment of Fah-positive hepatocytes. It was noteworthy that the level of liver repopulation in recipients transplanted with c-Kit Ϫ EpCAM ϩ cells at 10 weeks (24% Ϯ 15%) was significantly higher than those transplanted with day 13 unsorted cells (Ͻ5%) (Figure 4E and  F) . In addition, no teratomas or other tumors were found in any of the transplanted recipients. Therefore, we concluded that mouse ES cell-derived day 13 hepatic cells with liver repopulation capacity were restricted to the c-Kit Ϫ EpCAM ϩ cell population.
Clonally Expanded c-Kit ؊ EpCAM ؉ Cells Were Capable of Long-Term Expansion and Maintained Hepatoblast-Like Characteristics
To determine the capacity for in vitro expansion, single day 13 c-Kit Ϫ EpCAM ϩ cells were seeded into 96-well plates, and growth was promoted by mitomycin Ctreated MEF feeders in hepatoblast culture medium (see Materials and Methods section). Single c-Kit Ϫ EpCAM ϩ cells were able to expand into epithelial colonies ( Figure 5A ). Seven out of 9 colonies (labeled as clones 1, 3, 4, 6, 7, 8, 9) were successfully expanded by serial passages. Similar 
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to day 13 c-Kit Ϫ EpCAM ϩ cells (Figure 1B) , the cloned cells displayed representative epithelial and clonal morphology ( Figure 5A) ; they also expressed most hepatoblast-specific genes such as Afp, Alb, Ttr, Foxa2, Ck18, and Ck19 ( Figure 5B and Supplementary Table 1), as well as known hepatoblast-related surface antigens such as CD29, CD49f, EpCAM, 25, 29, 30 but were negative for c-Kit, CD34, and CD45 (Supplementary Figure 5A) . For further characterization, 2 cloned cell lines (Clone.4 and Clone.7) were picked out and expanded. During in vitro expansion, these cells could be harvested, frozen, and thawed repeatedly. After expansion for at least 3 months (Ͼ30 passages), there was no significant morphologic change ( Figure 5A ). There were similar population doubling times (30.95 hours for Clone.4 cells and 30.25 hours for Clone.7 cells, Supplementary Figure 5B ) and normal karyotype (Supplementary Figure 5C) , which suggested that these clonally derived cells were stable in genotype and phenotype during in vitro expansion.
We investigated whether our clonally expanded cells retain the bipotency to mature into hepatocyte-like or cholangiocyte-like cells. When cultured under conditions known for hepatic maturation, 26,32 cells from both Clone.4 and Clone.7 were able to differentiate into cells characteristic of mature hepatocytes with a large cytoplasm to nuclear ratio, numerous vacuoles and vesicles, and prominent nucleoli 26, 32 ( Figure 6A, panel a and b) . In addition, the differentiated cells could functionally metabolize Indocyanin Green ( Figure 6A , panel c), store glycogen ( Figure 6A, panel d) , and express mature hepatocyte-specific transcripts such as Cps1, G6p, Cyp3a11, and Cyp7a1 ( Figure 6A , panel e). In 3-dimensional culture conditions known to induce cholangiocytes, 26 ,32 expanded cells differentiated into cells with representative 
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branching structures ( Figure 6B, panels a and b) and expressed Ck7, Ck19, Hnf1b, Inetgrein-b4, and Ggt1 26, 32 ( Figure 6B, panels b and c) , indicative of cholangiocytic properties. These results indicated that clonally expanded c-Kit Ϫ EpCAM ϩ cells retained hepatoblast-like bipotency after long-term expansion.
Clonally Expanded c-Kit ؊ EpCAM ؉ Cells Retained Capacity for Therapeutic Liver Repopulation After Long-term Expansion
Cells expanded from Clone.4 and Clone.7 were labeled with GFP (Supplementary Figure 6) and then transplanted into Fah-deficient mice to determine their capacity for therapeutic liver repopulation. At 10 weeks after cell transplantation, we found liver repopulation in 3 of 7 recipients transplanted with Clone.4-GFP cells and 4 of 9 recipients transplanted with Clone.7-GFP cells. Fah ϩ hepatocytes were found in repopulation nodules derived from Clone.4-GFP cells or Clone.7-GFP cells, were similar in morphology, and the levels of liver repopulation were comparable with those from day 13 c-kit Ϫ EpCAM ϩ cells ( Figure 6C,  panel a and c) . Moreover, teratomas or other tumors were not detected. Of note, Fah ϩ hepatocytes in serial sections of repopulation nodules also stained positive for GFP ( Figure 6C, panel b and d) . These results indicated that clonally expanded c-Kit Ϫ EpCAM ϩ cells re- tained the capacity of therapeutic liver repopulation after long-term expansion.
Discussion
Pluripotent stem cell-derived hepatic cells hold great promise for therapeutic applications and may also be used in drug discovery and as models of human liver diseases. [1] [2] [3] There is much interest in generating functional hepatic cells of high quality in large quantities. 4 -16 In the present study, we aimed to establish a novel method to obtain renewable ES cell-derived hepatoblastlike progenitor cells with therapeutic liver repopulation capacity.
Our strategy focused on deriving hepatic progenitor cells rather than mature hepatic cells. Compared with mature hepatic cells, hepatic progenitor cells have obvious advantages: They are more easily manipulated in vitro without losing viability and differentiation potential. [33] [34] [35] They proliferate extensively during long-term expansion in vitro. [25] [26] [27] [28] [29] [30] 34 The novelties of our methods are as follows: First, the differentiation process was carried out under defined monolayer culture conditions, which allowed us to monitor directly the morphologic dynamics and to improve differentiation efficiencies during 2 differentiation steps. Second, our differentiation protocol successfully excluded differentiation of VE cells that are similar to DE cells in morphology and gene expression but have no hepatic differentiation potential. 20, 24 This approach enabled efficient hepatic differentiation from DE cells. Third, we were able to enrich for DE cells by defined culture techniques and without FACS sorting as was shown in previous reports. 5, 20 Even though there was a minor population of mesodermal cells present at day 5, DE cells as the major population pro- ceeded with hepatic differentiation, suggesting that the mesodermal cells did not negatively influence this process. Indeed, the hepatic colonies were found in proximity to fibroblast-like cells, which should be derived from mesoderm cells along with plated DE cells. We speculate that the fibroblast-like cells might provide physical support and/or secreted factors to promote hepatic cells differentiation and proliferation as previously revealed in vivo. 21, 22 Currently, no specific surface markers are available for identification and enrichment of ES cell-derived hepatic progenitor cells. After comparing surface markers previously used to isolate hepatic cells, 11, 25, 26, 29, 30 we selected several of them as candidates including EpCAM, Flk1, and CD45. EpCAM was found on hepatic progenitor cells rather than adult hepatocytes. [25] [26] [27] [28] In addition, EpCAM is also found on ES cells and DE cells (Figure 2A ). Therefore, usage of EpCAM was not enough to enrich ES cell-derived hepatic progenitor cells. We then searched for additional markers and also considered the strategy of negative selection to exclude potential non-hepatic cells from the EpCAM ϩ cell population. Because c-Kit was only expressed on ES cells, DE cells, and some mesoderm cells but not hepatic cells, 5, 29, 30 the combination of c-kit in negative selection with EpCAM in positive selection was considered to select ES cell-derived hepatic progenitor cells. Based on EpCAM and c-Kit expression, we found that the cells at day 13 of differentiation could be sorted into 4 cell populations. Among them, the c-Kit Ϫ EpCAM ϩ cell population carried the properties of hepatic progenitor cells, which was proved by rigorous gene expression analysis and morphologic examination. Regarding the 3 other cell populations, c-Kit ϩ EpCAM ϩ population contained residual DE cells, whereas c-Kit Ϫ EpCAM Ϫ and c-Kit ϩ EpCAM Ϫ populations contained mesoderm cells. Furthermore, the liver repopulation capacity of c-Kit Ϫ EpCAM ϩ cells further supported the hepatic progenitor cell phenotype. For the first time, we successfully identify the applicable surface markers to recognize mouse ES cell-derived hepatoblast-like progenitor cells. Consistent with our results, EpCAM has been recently found on human ES cell-derived hepatic progenitors. 12 However, EpCAM was not tested as a selection marker in this study previously.
We applied a single cell-derived cloning selection assay as another strategy to enrich ES cell-derived hepatic progenitor cells into purity. 32 We found that clonally expanded cell lines could be established from single c-Kit Ϫ EpCAM ϩ cells. These cloned cells sustained longterm expansion and retained hepatoblast-like characters and liver repopulation capacity, indicating that we obtained renewable hepatic progenitor cells from ES cells.
As one of the well-established animal models for liver repopulation assays, Fah-deficient mice were previously used to determine the liver repopulation capacity of ES cell-derived hepatic cells. 5, 36 However, the conclusions from 2 independent groups were controversial. The results of one group showed detectable but low liver repopulation from ES cell-derived hepatic cells, 5 whereas that from another group showed that ES cell-derived hepatic cells had no liver repopulation after liver engraftment. 36 We speculate that these discrepancies can be explained by several differences in their studies, such as the methods used to derive and isolate the ES cell-derived hepatic cells. It is still hard to compare directly the results from each individual group. Consistent with one group, we found ES cell-derived hepatic cells with capacity for liver repopulation. Our unsorted cells could repopulate the injured livers of Fah-deficient mice at a low level (Ͻ5%), and the c-Kit Ϫ EpCAM ϩ cells reached a significantly higher level of liver repopulation (24% Ϯ 15%), indicating that purification of c-Kit Ϫ EpCAM ϩ cells substantially improved the liver repopulation. Our results showed higher levels of repopulation by ES cell-derived hepatic cells than those in previous publications, which strongly suggest that we have obtained a successful strategy to enrich for hepatic progenitor cells with liver repopulation capacity. Furthermore, we did not find tumors in recipients of Fah-deficient mice after 10 weeks of cell transplantation. Although a longer term experiment will be necessary to characterize the full extent of liver repopulation and to rule out tumorigenesis, our current results suggest that tumorigenesis was not an issue during a 10-week time frame of liver repopulation.
In summary, this is the first approach in identification and expansion of ES cell-derived hepatic progenitor cells with therapeutic liver repopulation capacity. Our work provides insights toward the isolation of human pluripotent stem cell-derived hepatic progenitor cells for potential therapeutic applications.
Supplementary Materials and Methods
Reverse-Transcription Polymerase Chain Reaction and Quantitative Polymerase Chain Reaction
Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA) and treated with RNase-free DNase I (Qiagen), and 0.5 g RNA was reverse transcribed into complementary DNA (cDNA) with random hexamers using First Strand cDNA Synthesis Kit ReverTra Ace -a-(Toyobo, Osaka, Japan). Polymerase chain reaction (PCR) was performed with 1/20 of cDNA in 20 L reaction volume containing Taq DNA polymerase (Tiangen, Beijing, China). Cycling conditions were as follows: 94°C for 5 minutes, followed by 25 to 35 cycles of amplification (denaturation at 94°C for 30 seconds, annealing for 30 seconds, elongation at 72°C for 1 minute), with a final incubation at 72°C for 5 minutes. Amplified products were separated by electrophoresis on a 2% agarose gel and stained with ethidium bromide. RNA from embryonic day 13. To induce hepatic maturation, 1,2 clonally expanded c-Kit Ϫ EpCAM ϩ cells depleted of feeder cells were seeded in type I collagen-coated dishes in the maintaining medium for 4 days until confluence, then the medium was changed to serum-free maturation medium (chemically defined medium supplemented with 10 ng/mL epidermal growth factor [EGF], 10 ng/mL hepatocyte growth factor [HGF], 10 Ϫ7 mol/L dexamethasone, 1% dimethyl sulfoxide, and 10 ng/mL Oncostatin M) for 6 days, and medium was changed every other day.
For cholangiocytic differentiation, 1,2 clonally expanded c-Kit Ϫ EpCAM ϩ cells depleted of feeder cells were cultured in type I collagen gel (Becton Dickinson, San Jose, CA) according to the manufacturer's protocol. One ϫ 10 5 cells resuspended in 1 mL Dulbecco's modified Eagle medium (DMEM)/F12 medium were mixed with 1 mL freshly prepared collagen gel solution, poured into a 35-mm dish, and cultured at 37°C for 2 hours to solidify the gel then filled with 1.5 mL differentiation medium (DMEM/F12 supplemented with 10% fetal bovine serum [FBS] , 1X insulin-transferrin-selenium X [ITS], 50 mg/mL gentamicin, 20 ng/mL HGF) and cultured for 9 days. To examine expression of cytokeratin 19 (Ck19) by immunostaining, collagen gels were fixed with 4% paraformaldehyde and permeabilized using 0.5% Triton X-100/phosphate-buffered saline (PBS). After blocking and washing, the gels were incubated with primary antibody and then secondary antibody, followed by examination under an Olympus IX41 (Olympus Corporation, Tokyo, Japan) fluorescence microscope.
Periodic Acid-Schiff Staining and Indocyanin Green Uptake Assay
Periodic acid-Schiff staining was performed with a periodic acid-Schiff Kit (Sigma-Aldrich, St. Louis, MO) according to the manufacturer's instructions. Indocyanin green (ICG) uptake assay was performed with 1 mg/mL ICG (Sigma-Aldrich) in the culture medium at 37°C for 30 minutes, followed by washing 3 times with PBS. Cellular uptake of ICG was examined by microscopy. ICG was completely eliminated from the cells 6 hours later.
Calculating the Population Doubling Time of Clonally Expanded Cells
Cells of Clone.4 (P37) or Clone.7 (P34) were cultured (2 ϫ 10 5 cells/well) in duplicate in wells of 12-well plates pre-cultured with mouse embryonic fibroblasts feeders, and the cell numbers were counted at 24 hours, 48 hours, 72 hours, and 96 hours later. The growth curves were drawn, and the population doubling times were calculated using the algorithm provided by http:// www.doubling-time.com.
Karyotyping Analysis
Clonally expanded cells depleted of feeders were cultured in a 60-mm dish until 80% confluence. Cells were treated with colcemid (0.1 g/mL, final concentration) for 2 hours before harvesting. Cells were washed with PBS, trypsinized, transferred into 15-mL tubes, and were centrifuged with the supernatant removed and resuspended with 10 mL KCl solution (75 mmol/L). The cell mixtures were then incubated for 30 minutes in 37°C water bath and then fixed by adding 1 mL fresh fixative solution (methanol/acetic acid, 3:1). The fixed cells were washed at least 3 times with 10 mL of fixative solution before being applied onto chilled slides. The slides were air-dried, stained with 4=,6-diamidino-2-phenylindole, and observed under a fluorescent microscope. For each cell line, at least 40 fields of individual colonies with clearly spread chromosomes were examined.
Lentivirus Production and Infection of Clonally Expanded c-Kit ؊ EpCAM ؉ Cells
293T cells in a 60-mm dish were cotransfected by using Fugene HD (Roche Diagnostics, Basel, Switzerland) with the following plasmids: psPAX2, pMD2G, and pWPT-GFP (Addgene Inc, Cambridge, MA). Forty-eight hours later, the supernatant containing lentivirus was collected, filtered, and added to clonally expanded c-Kit Ϫ EpCAM ϩ cells in a 6-well plate for 6 hours. Infected cells were passaged, and the green fluorescent proteinpositive cells were purified by fluorescence-activated cell sorter and expanded.
